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Objective: To evaluate whether hypoxia inducible factor (HIF-1a) targeting pharma-
cological drugs, echinomycin, resveratrol and CdCl2 which inhibit HIF-1a stimulation,
and mimosine, which enhances the stability of HIF-1a present antileishmanial properties.
Methods: The leishmanicidal effect of drugs was evaluated in mouse macrophages and
Balb/c mouse model for cutaneous leishmaniosis.
Results: Resveratrol and CdCl2 reduced the parasite load [IC50, (27.3 ± 2.25) mM and
(24.8 ± 0.95) mM, respectively]. The IC50 value of echinomycin was (22.7 ± 7.36) nM
and mimosine did not alter the parasite load in primary macrophages. The macrophage
viability IC50 values for resveratrol, echinomycin and CdCl2 and mimosine were
>40 mM, >100 nM, >200 mM and>2000 mM, respectively. In vivo no differences be-
tween cutaneous lesions from control, resveratrol- and echinomycin-treated Balb/c mice
were detected.
Conclusions: Resveratrol, echinomycin and CdCl2 reduce parasite survival in vitro. The
HIF-1a targeting pharmacological drugs require further study to more fully determine
their anti-Leishmania potential and their role in therapeutic strategies.1. Introduction
Leishmanioses are diseases caused by intracellular Leish-
mania parasites of macrophages [1] and they are endemic in
more than 90 countries [2] Leishmania amazonensis
(L. amazonensis) is transmitted mainly in the Amazon region
and causes localized and diffuse cutaneous lesions and
mucosal infection [3]. Leishmanioses are neglected diseases,
there is no vaccine, current therapies fail to eradicate parasites
from infected tissues and present side effects, while resistance
to classical chemotherapy has become a clinical threat [2,4].
Recently our group and others have shown that mice with
cutaneous leishmaniosis present hypoxic areas in damaged and
infected tissues [5–7] and that Leishmania-infected macrophagesfrom lesions and infected macrophage cultures accumulate
hypoxia inducible factor (HIF-1a) [8–11]. HIF is a
heterodimeric transcription factor consisting of HIF-1a and
HIF-1b [12]. Under normoxia, HIF-1a is hydroxylated on
proline residues and degraded by the ubiquitin proteasome
pathway while under hypoxia, hydroxylation is inhibited and
heterodimerization, nuclear translocation and transcription of
HIF-dependent genes such as erythropoietin, vascular endothe-
lial growth factor and transferrin occur [12–14]. HIF-1a
overexpression is observed in a wide array of tumor cells that
reprogram the metabolism for the induction of glycolytic
enzymes [14]. Thus HIF-1a is originally identiﬁed as a master
regulator of the adaptive response to diminished oxygen
supply and accumulates in ischemic tissues and various types
of cancer and their metastases; HIF-1a overexpression may
trigger cell invasion and is associated with treatment failure
[15,16]. The current understanding that HIF-1a can be
expressed during infection with bacteria, such as Chlamydia
[17] viruses, such as Epstein Barr [18] and protozoa, such as
Leishmania and Theileria [8,9,19] via oxygen-dependent and
oxygen-independent pathways reveals its additional role as a
transcriptional regulator of inﬂammation and infection [20].
Experimental therapeutics involving the pharmacological
modulation of HIF-1a has became a promising novel strategy;icle under the CC BY-NC-ND license (http://
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through cell-based screening [15,16,21] and tests for various
carcinogenesis and ischemic disease models have been
reported in recent years [22–26].
Since sustained efforts are required to enrich new anti-
leishmanial drug discovery, we aimed to evaluate whether
echinomycin, a compound that inhibits the DNA binding ac-
tivity of HIF-1a [27], resveratrol which inhibits HIF-1a though
multiples mechanisms, including HIF protein degradation via
the proteasome pathway [28] cadmium (CdCl2), which is a
heavy metal that triggers proteasome-dependent degradation of
HIF-1a [29], and mimosine, a hydroxylase inhibitor agonist that
stabilizes HIF-1a [30] present antileishmanial properties.
2. Material and methods
2.1. Reagents
Echinomycin, C51H64N12O12S2, was purchased from Alexis
Biochemicals (San Diego, CA, USA), L-mimosine, C8H10N2O4,
was purchased from Enzo Life Sciences (Lausen, Switzerland),
resveratrol, C14H12O3, and cadmium chloride, CdCl2, were
purchased from Sigma–Aldrich (St. Louis, MO, USA), and
meglumine antimoniate (glucantime) was purchased from
Sanoﬁ-Aventis (São Paulo, Brazil). Each of these compounds
was dissolved in phosphate-buffered saline (PBS) or RPMI
medium, resveratrol was dissolved in RPMI medium using small
amounts (<0.01%) of dimethyl sulfoxide (DMSO) as required.
Unless otherwise stated, all other reagents were obtained from
Sigma–Aldrich.
2.2. Cell culture and parasites
Peritoneal mouse macrophages were obtained from normal
BALB/c mice by peritoneal lavage, as previously described [31].
The cells were cultured in RPMI medium supplemented with
100 U/mL penicillin, 100 mg/mL streptomycin and 10% fetal
calf serum (Cultilab, Campinas, SP, Brazil) at 37 C in 5%
CO2, 5% O2 and balanced N2. L. amazonensis (MHOM/BR/
73/M2269) amastigotes were isolated from active skin lesions
of BALB/c mice [32].
2.3. Assessment of the effect of drugs on L. amazonensis
infected macrophages
Macrophages (5 × 105 cells/well) cultured in 24-well cell
culture plates containing 13 mm diameter glass coverslips were
exposed to L. amazonensis at a parasite/macrophage ratio of
3:1 for 2 h. Following exposure, the cultures were washed to
remove extracellular parasites and then incubated in the pres-
ence of the drugs for 48 h. To evaluate the parasite load
(number of amastigotes per macrophage), cells on coverslips
were stained with Giemsa. The intracellular amastigotes, which
are located exclusively in parasitophorous vacuoles, and
200 cells were examined microscopically at 1000 magniﬁca-
tion [31]. All tests were performed in triplicate. The reduction in
parasite load induced by the compounds was calculated as a
percentage of the control (assuming 100% parasite load of
untreated macrophages). The IC50 describes the drug
concentration that inhibits 50% of parasite load and was
calculated using a curve ﬁtting program (GraphPad Prism 6software). Cellular viability was assessed by counting the
adherent cells in 20 random ﬁelds of infected and uninfected
macrophage cultures [33]. The IC50 describes the drug
concentration that inhibits 50% macrophage viability and,
was calculated using a curve ﬁtting program (GraphPad
Prism 6 software).
2.4. Assessment of the effect of drugs on L. amazonensis
infected mice
The Ethics Committee for Animal Research of the Institute of
Biology of the State University of Campinas approved the
experimental protocols. Six-week-old female BALB/c mice
were subcutaneously inoculated in the right hind footpad with
105 amastigotes. For each group of mice, 3 per group were
administered the same vehicles (PBS and DMSO) without
the compounds, resveratrol 15 mg/kg/day, echinomycin
0.13 mg/kg/day or glucantime 100 mg/kg/day [33–36] injected
intraperitoneally for 20 d, 26 d after parasite inoculation. The
course of infection was monitored by measuring the increase
in footpad thickness with a dial caliper, compared with the
contra lateral uninfected footpad [33]. This study was approved
by the Ethics Committee of Universidade Estadual de
Campinas (process numbers: 1742-1 and 2715-1).
2.5. Immunoblot analyses
The macrophages were scraped from the culture ﬂasks and
rinsed twice with PBS. Lysis buffer (62.5 mM Tris–HCl, pH
6.8, 69 mM SDS, 10% glycerol, 2% 2-mercaptoethanol,
34 mM ethylenediaminetetraacetic acid, 2 mg/mL pepstatin
and 1 mM phenylmethylsulfonyl ﬂuoride) (Amersham Phar-
macia Biotech, Piscataway, NJ, USA) was added to the cell
pellets. Proteins were denatured at 95 C for 3 min, electro-
phoresed on a 10% SDS-PAGE (poly-acrylamide) gel system
(Thermo EC, USA) and transferred to nitrocellulose mem-
branes (Amersham Pharmacia Biotech). After blotting, mem-
branes were probed with rabbit polyclonal anti-HIF-1a
antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA
and Sigma–Aldrich) and secondary antibody peroxidase-
conjugated goat anti-rabbit IgG (Amersham, Poole, UK and
Sigma–Aldrich); development was performed with 3,3-
diaminobenzidine. Immunoreaction images were scanned and
the densitometric value of each band was determined using
Image Master Total Lab version 1 software (Amersham
Pharmacia Biotech).
2.6. Immunoﬂuorescence analyses
Cells attached to the slide-chambers were ﬁxed for 10 min
with 4% paraformaldehyde and washed 3 times in PBS. The
cells were permeabilized with 1% Tween 20 and then washed
twice in PBS. Nonspeciﬁc binding sites were blocked with 3%
BSA (Amresco, Solon, OH, USA) for 30 min. The macrophages
were then incubated with mouse anti-L. amazonensis serum or
anti-HIF-1a antibody (Santa Cruz Biotechnology) overnight at
4 C in a wet room. The cells were washed 4 times in
PBS + 0.1% Tween 20 and incubated with FITC-conjugated
goat anti-mouse secondary antibody or FITC-conjugated goat
anti-rabbit secondary antibody for 1 h in a wet room at room
temperature. The cells were washed four times in PBS + 0.1%
Table 1
In vitro antileishmanial and cytotoxicity of HIF-1a targeting drugs.
Drugs IC50
Intracellular amastigotesa Macrophagesb
Resveratrol 27.3 ± 2.25 mM >40 mM
CdCl2 24.8 ± 0.95 mM >200 mM
Echinomycin 22.7 ± 7.36 nM >100 nM
Mimosine >80 mM >2000 mM
a Drug concentration that inhibit 50% of the parasite load (number of
amastigotes per macrophage) at 48 h incubation time. b Drug concen-
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mounting media. The cells were visualized under a Nikon
Eclipse 50i ﬂuorescence microscope (Nikon, Melville, NY,
USA). All images were captured and analyzed with a digital
camera (Nikon DXM1200-F) and imaging software (ACT-1,
Nikon).
2.7. Statistical analyses
All the experiments were repeated at least three times for
in vitro assays and twice for in vivo assays. Statistical signiﬁ-
cance between the control and experimental groups were
determined by the Student t test and the resulting data are
expressed as the mean ± SD.
3. Results
3.1. Expression of HIF-1a in Leishmania-infected
macrophages
Leishmania is an intracellular parasite that interferes with
HIF-1a expression in vitro and in vivo [9]. The
immunoﬂuorescence analyses conﬁrmed that under the chosen
experimental conditions intracellular amastigotes were
established inside macrophages with (8.9 ± 3.2) parasites per
infected cell (Figure 1A–B). The intensity and pattern of HIF-
1a immunostaining were similar between macrophage cultures
in normoxia (21% O2) and hypoxia (2% O2) (Figure 1C–D),
conﬁrming that Leishmania activates HIF-1a in macrophages
[8,9]. HIF-1a was expressed in L. amazonensis infected
macrophages, as shown in the western blots, and was reduced
following treatment with resveratrol, echinomycin and CdCl2
(Figure 1E).Figure 1. HIF-1a expression in L. amazonensis infected macrophages.
Fluorescent images of infected macrophages under normoxia labeled with ant
infected macrophages under hypoxia labeled with anti-L. amazonensis serum (g
antibody (DAPI image, right side) (C); or labeled with anti-HIF-1a antibody
macrophages nontreated (1) or treated with resveratrol 50 mM; (2) echinomyci3.2. Effect of HIF-1a targeting pharmacological drugs
on viability of macrophages
The dose range of the pharmacological drugs used in the
antileishmanial assays were chosen based on macrophage
viability data for each compound; the IC50 values obtained for
resveratrol, echinomycin, CdCl2, and mimosine were >40 mM,
>100 nM, >200 mM, and>2000 mM, respectively (Table 1);
these results corroborate previous ﬁndings [9,34,37–39].
3.3. Effect of HIF-1a targeting pharmacological drugs
on Leishmania within macrophages
Next, the compoundswere tested in antileishmanial assays. The
IC50 values of each drug are listed in Table 1. Resveratrol, CdCl2
and echinomycin reduced the parasite load after 48 h of treatment
[IC50 (27.30± 2.25)mM, (24.80± 0.95)mMand (22.70± 7.36) nM,
respectively]. Mimosine did not inhibit signiﬁcantly the parasite
load in L. amazonensis infected macrophages under the conditions
tested (IC50 > 80 mM) (Table 1). Similar results were obtainedi-L. amazonensis serum (green) and nuclei labeled with DAPI (blue) (A);
reen) and nuclei labeled with DAPI (blue) (B); or labeled with anti-HIF-1a
(DAPI image, right side) (D). Western blots (E) of extracts from infected
n 10 nM; (3) CdCl2 25 mM; (4) or mimosine 50 mM for 24 h.
tration that inhibit 50% of the macrophage viability at 48 h incubation
time.
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exception was L. amazonensis infected J774 macrophage cultures,
which reduced the parasite load after mimosine treatment: IC50
(56.00 ± 1.51) mM. The IC50 value of a reference anti-Leishmania
drug, amphotericin B was (0.040 ± 0.002) mM but a complete
reduction of infection was not obtained [33].
3.4. Effect of resveratrol and echinomycin on
Leishmania-infected mice
Since resveratrol and echinomycin have been tested in
various animal models of cancer and other diseases [22,27,28,34],
both compounds were evaluated in mice. Observation of
individual footpad sizes of L. amazonensis infected Balb/c
mice over time detected no signiﬁcant differences between
PBS/DMSO, resveratrol and echinomycin treatments; lesion in
individual mouse progressively increased in size (Figure 2). In
this experiment, three of the ﬁve (60%) echinomycin-treated
mice died prematurely. No mortality was observed in PBS/
DMSO- and resveratrol-treated mice; similar results were ob-
tained in another independent experiment. Glucantime, which is
used in the clinical treatment of leishmaniosis, prevented lesions
(Figure 2) and ulcerations developed slowly, although a com-
plete cure was not obtained.Figure 2. Effects of HIF-1a target drugs on L. amazonensis infection.
Balb/c mice (3 per group) were treated intraperitoneally with PBS/DMSO
(-,:, C), glucantime (100 mg/kg/day) (▫, △,B), resveratrol (15 mg/
kg/day) (*, −, +) or echinomycin 0.13 mg/kg/day (rhombuses) for 20 d,
26 d after parasite inoculation with 105 amastigotes in the footpad. Lesion
size is expressed as the difference in size between the infected and the
contra lateral uninfected footpads.4. Discussion
The modulation of HIF-1a has been an interesting chemo-
therapy approach for many diseases and drugs that achieve this
could be repositioned as infectious disease therapeutics [20].
Recently we showed that HIF-1a is activated during
L. amazonensis infection [5,7–9]. The picture emerging from
these studies is that HIF-1a induction and the target genes
constitute part of an adaptation mechanism resulting from
Leishmania infection and that this could permit the
macrophage to attenuate damage, maintain integrity and
survive the infection [9], since HIF-1a transcriptionalregulation can support microbicidal and inﬂammatory
phenotypes [20,24]. Reports on the anti-microorganism proper-
ties of HIF-1a modulating drugs are scarce.
The addition of CdCl2 to L. amazonensis infected macro-
phage cultures signiﬁcantly reduced parasite survival, conﬁrm-
ing our previous data [9]. Cadmium is a heavy metal that triggers
proteasome-dependent degradation of HIF-1a protein,
depressing its activity as a hypoxia mimic; CdCl2 was used only
as an in vitro control since it is classiﬁed as a human carcinogen
[40].
Our results also indicated that resveratrol reduced parasite
survival in macrophage cultures. In fact, resveratrol anti-Leish-
mania in vitro activity has also been reported for L. major [41]
and the authors speculated that resveratrol could exert anti-
proliferative activities in promastigotes and intracellular amas-
tigotes through the inhibition of tubulin polymerisation. Since
resveratrol downregulate HIF-1a expression [22] and it is a
transcription factor that can reprogram the cell metabolism
[14], we suggest that the antileishmanial effect of resveratrol
could be linked to negative modulation of HIF-1a in host
macrophages. Our data showed that resveratrol did not have a
signiﬁcant effect on the reduction of Balb/c mice lesion, even
though it is nontoxic in rodents [42]. The animal model of
infection chosen was Balb/c mice, the most used in vivo
model for experimental studies because infection with
cutaneous Leishmania results in very aggressive and non-
healing cutaneous lesions [43]. Future investigation of
resveratrol treatment in other mouse strains and different
Leishmania species would assist in a fuller understanding of
how this drug effects the progression of different leishmanioses.
Echinomycin is a cyclic depsipeptide antibiotic which has
been described as inhibiting HIF-1a DNA binding and tran-
scription activity [27,28]. It is reported to have antitumor and
antibacterial activity, despite a low toxicity in Trypanosoma
brucei and T. rhodesiense [44] and showed no in vivo
antileishmanial effect (our data). In fact, administration of
echinomycin induced lethality in Balb/c mice, even though
previous toxicological evaluation performed in mice and dogs
indicated that the clinical signs induced by the drug, such as
hypoactivity, ataxia and weight loss, were reversed [34]. The
reasons for this discrepancy are unclear but it is possible that
L. amazonensis infected mice are more sensitive to the drug
than uninfected mice.
Mimosine is an alkaloid that stabilizes HIF-1a and boosts the
capacity of human neutrophils to kill Staphylococcus aureus [30].
Our data shown that mimosine did not have a signiﬁcant effect
on the parasite load in L. amazonensis infected primary
macrophages, with the exception of the L. amazonensis
infected J774 macrophage cell line. As previously shown, the
compound did not inhibit the growth of L. donovani
promastigotes, but had effect on amastigotes within a
macrophage cell line [45]. The authors suggested that the anti-
Leishmania activity of mimosine is related to its inhibitory
activity in deoxyhypusine hydroxylase, an enzyme involved in
cell proliferation [45]. The differences in sensitivity between
Leishmania species and macrophage origins to mimosine and
its mechanism of action could be explored for drug
development.
In conclusion, analysis of our results suggests that HIF-1a
modulation require further study to more fully determine the
anti-Leishmania potential of HIF-1a modulator compounds and
their role in therapeutic strategies.
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